RxDoctor Payments Data

Lesly Robinson, DPM

Podiatrist · Wilmington, DENPI 1629081922

Payments from drug & device makers

What this record shows

22 manufacturers reported payments, led by Osiris Therapeutics Inc. at 46.4% of the total. Reporting peaked in 2019 at $1,767 and has fallen 71.8% since, to $498 in 2025.

$3,289in general payments, 2019–2025

Across 91 payments — averaging $36.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Osiris Therapeutics Inc.$2K
  • Smith+Nephew$768
  • Organogenesis Inc.$305
  • Kerecis Limited$147
  • Reapplix Inc.$58
  • AstraZeneca$58
  • plus $427 from 16 others
$99,115in research payments, 2019–2025

Across 17 payments — averaging $5830.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Smith+Nephew$87K
  • Osiris Therapeutics Inc.$12K

What the payments were for

  • Speaking & faculty fees$1,50046%
  • Food & beverage$1,78954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,289 in reported general payments places this provider in the 70th percentile of 37 podiatrist providers in Delaware.

See all podiatrist providers in Delaware

Medicare billing

Part B allowed, 2024
$21,441
Medicare patients
95
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox179$4,319
Ammonium Lactate122$2,521
Ketoconazole127$2,473
Clindamycin Phosphate13$337
CiclopiroxCiclopirox Olamine12$222
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$184
Duloxetine Hcl11$73

Paid to pharmacies, not to this prescriber.

Other podiatrist in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →